Free Trial

IQVIA (IQV) Stock Price, News & Analysis

IQVIA logo
$162.73 -2.80 (-1.69%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$161.78 -0.95 (-0.59%)
As of 09:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IQVIA Stock (NYSE:IQV)

Key Stats

Today's Range
$161.36
$164.89
50-Day Range
$136.96
$165.53
52-Week Range
$134.65
$252.88
Volume
1.16 million shs
Average Volume
1.65 million shs
Market Capitalization
$28.15 billion
P/E Ratio
22.17
Dividend Yield
N/A
Price Target
$222.45
Consensus Rating
Moderate Buy

Company Overview

IQVIA Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
99th Percentile Overall Score

IQV MarketRank™: 

IQVIA scored higher than 99% of companies evaluated by MarketBeat, and ranked 25th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IQVIA has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 16 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IQVIA has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about IQVIA's stock forecast and price target.
  • Earnings Growth

    Earnings for IQVIA are expected to grow by 12.55% in the coming year, from $10.84 to $12.20 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IQVIA is 22.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.16.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IQVIA is 22.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.28.

  • Price to Earnings Growth Ratio

    IQVIA has a PEG Ratio of 1.81. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IQVIA has a P/B Ratio of 4.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about IQVIA's valuation and earnings.
  • Percentage of Shares Shorted

    5.28% of the float of IQVIA has been sold short.
  • Short Interest Ratio / Days to Cover

    IQVIA has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IQVIA has recently decreased by 3.00%, indicating that investor sentiment is improving.
  • Dividend Yield

    IQVIA does not currently pay a dividend.

  • Dividend Growth

    IQVIA does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.28% of the float of IQVIA has been sold short.
  • Short Interest Ratio / Days to Cover

    IQVIA has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IQVIA has recently decreased by 3.00%, indicating that investor sentiment is improving.
  • News Sentiment

    IQVIA has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for IQVIA this week, compared to 19 articles on an average week.
  • Search Interest

    16 people have searched for IQV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added IQVIA to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IQVIA insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.60% of the stock of IQVIA is held by insiders.

  • Percentage Held by Institutions

    89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IQVIA's insider trading history.
Receive IQV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.

IQV Stock News Headlines

IQVIA Holdings (IQV) Receives a Buy from Leerink Partners
IQVIA (NYSE:IQV) Given New $180.00 Price Target at Evercore ISI
The DOJ Just Paved the Way for Account Seizures
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
IQV - IQVIA Holdings Inc Chart | Morningstar
See More Headlines

IQV Stock Analysis - Frequently Asked Questions

IQVIA's stock was trading at $196.51 on January 1st, 2025. Since then, IQV shares have decreased by 17.2% and is now trading at $162.73.

IQVIA Holdings Inc. (NYSE:IQV) posted its quarterly earnings data on Tuesday, May, 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The business's revenue for the quarter was up 2.5% compared to the same quarter last year.
Read the conference call transcript
.

IQVIA subsidiaries include these companies: Q2 Solutions, Linguamatics, Advanced Health Media LLC, DrugDev, Aileron Solutions, Novella Clinical LLC, 159 Solutions LLC, and others.

Top institutional shareholders of IQVIA include Assenagon Asset Management S.A. (0.12%), Community Trust & Investment Co. (0.07%), Swedbank AB (0.05%) and Czech National Bank (0.02%). Insiders that own company stock include Ari Bousbib, Eric Sherbet, Constantinos Panagos, Kevin C Knightly and John G Danhakl.
View institutional ownership trends
.

Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IQVIA investors own include NVIDIA (NVDA), Chevron (CVX), Meta Platforms (META), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD), Broadcom (AVGO) and McKesson (MCK).

Company Calendar

Last Earnings
5/06/2025
Today
7/13/2025
Next Earnings (Estimated)
7/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Business Services
Current Symbol
NYSE:IQV
CIK
1478242
Fax
N/A
Employees
88,000
Year Founded
2016

Price Target and Rating

High Price Target
$276.00
Low Price Target
$160.00
Potential Upside/Downside
+36.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
24 Analysts

Profitability

EPS (Trailing Twelve Months)
$7.34
Trailing P/E Ratio
22.17
Forward P/E Ratio
15.01
P/E Growth
1.81
Net Income
$1.37 billion
Net Margins
8.61%
Pretax Margin
10.66%
Return on Equity
29.16%
Return on Assets
6.96%

Debt

Debt-to-Equity Ratio
2.19
Current Ratio
0.82
Quick Ratio
0.82

Sales & Book Value

Annual Sales
$15.41 billion
Price / Sales
1.83
Cash Flow
$16.61 per share
Price / Cash Flow
9.80
Book Value
$33.43 per share
Price / Book
4.87

Miscellaneous

Outstanding Shares
173,000,000
Free Float
170,232,000
Market Cap
$28.15 billion
Optionable
Optionable
Beta
1.30

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NYSE:IQV) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners